Have you ever wondered what it’s like to be a medical oncologist? Follow our Dr. Eric Singhi throughout his day.
Eric K. Singhi, M.D.
Department of General Oncology, Division of Cancer Medicine
Meet Eric Singhi, M.D.
3 common myths about lung cancer
A day in the life of a medical oncologist with Dr. Eric Singhi
Featured Articles
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Medical University of South Carolina, Charleston, South Carolina, US, M.D |
| 2012 | Duke University, Durham, North Carolina, US, BS in Bachelor of Science in Neuroscience |
Postgraduate Training
| 2019-2022 | Chief Fellow, Hematology/Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Clinical Residency, Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee |
Licenses & Certifications
| 2022 | American Board of Internal Medicine - Hematology |
| 2022 | American Board of Internal Medicine - Medical Oncology |
| 2022 | Texas Medical Board |
| 2019 | American Board of Internal Medicine |
Experience & Service
Intramural Institutional Committee Activities
Director, Thoracic/Head and Neck Oncology Research, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Committee for Faculty Required Training (ComFRT), The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Artificial Intelligence and Digital Health GME, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Thoracic/Head and Neck Medical Oncology Lead for Clinical Effectiveness Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Ambassador, MD Anderson Community Ambassador for Lung Cancer, The University of Texas MD Anderson Cancer Center, 2024 - Present
Patient Safety Quality Officer, Patient Safety Quality Officer of Thoracic Oncology Service Line, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Thoracic/Head and Neck Medical Oncology Lead for Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Faculty Member, Thoracic Service Line Physician Leadership, The University of Texas MD Anderson Cancer Center, 2023 - Present
Physician Lead, Research Program/ Community Outreach & Engagement Physician Lead, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, General Oncology Grand Rounds, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Director, Thoracic Medical Oncology Rotation for Hematology/Medical Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Faculty Member, Clinical Competency Committee for Hematology/Medical Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, Thoracic/Head and Neck Medical Oncology Journal Club, The University of Texas MD Anderson Cancer Center, 2023 - Present
Faculty Member, Lung Cancer Center Support Grant (CCSG) Program, The University of Texas MD Anderson Cancer Center, 2023 - Present
Honors & Awards
| 2025 - Present | 40 Under 40 in Cancer 2024, ASCO |
| 2025 - Present | Top 100 Oncologists on Social Media, Larvol Oncology Data Intelligence |
| 2025 | Emerging Leader Alumni Award, Medical University of South Carolina College of Medicine |
| 2024 | Rising Star of MD Anderson, The University of Texas MD Anderson Cancer Center |
| 2024 | Top 100 Xfluencers in Lung Cancer, OncoDaily |
| 2024 | Top 100 Oncologists on Social Media, Larvol Oncology Data Intelligence |
| 2023 | Medical Spotlight Keynote Speaker Award, MedNews Week International |
| 2023 | International Association for Study of Lung Cancer (IASLC) Academy Awardee, International Association for Study of Lung Cancer (IASLC) |
| 2023 | Junior Faculty Travel Award, Hawaii Global Summit on Thoracic Malignancies |
| 2023 | MD Anderson Awesome Job Award, The University of Texas MD Anderson Cancer Center |
| 2023 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
| 2022 | MD Anderson Awesome Job Award, MD Anderson Cancer Center |
| 2022 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
| 2022 | Young Investigator Award, EGFR Resisters Research Summit |
| 2021 | Physician Educators Certificate Program (PECP), University of Texas Health Houston |
| 2021 - 2022 | Patient Education Ambassador, Global Resource for Advancing Cancer Education |
| 2016 | Gold Humanism Honor Society, Medical University of South Carolina |
| 2016 | Alpha Omega Alpha Honor Medical Society, Medical University of South Carolina |
| 2015 | Rich Merit Scholarship, Medical University of South Carolina |
| 2014 | Jean Wilson Endowed Merit Scholarship, Medical University of South Carolina |
| 2013 | Caroline B. Lown Merit Scholarship, Medical University of South Carolina |
| 2012 | Graduation with Distinction, Duke University |
| 2012 | Magna Cum Laude, Duke University |
| 2012 | Phi Beta Kappa, Duke University |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. ASCO 2025 Highlights of the Day Lung Cancer. Invited. ASCO. Chicago, IL, US.
- 2025. OncLive ASCO 2025 Early-Career Lung Cancer Discussion. Invited. OncLive ASCO. Chicago, IL, US.
- 2025. Oncology Forum-Lung Cancer Expert Panelist. Panelist, US.
- 2025. Young-Onset Lung Cancer Roundtable. Invited. Lung Cancers Today, US.
- 2025. Pioneering Oncology Through Molecular Tumor Boards Panel. Invited. Chicago, IL, US.
- 2025. OncLive National Fellows Forum Thoracic Oncology. Invited. Chicago, IL, US.
- 2025. Big Changes in Small Cell Lung Cancer. Invited. Gundersen Health Grand Rounds. Winona, MN, US.
- 2025. Important Advancements in Treating Early-Stage Non-Small Cell Lung Cancer. Invited. Lungevity HOPE Summit. Bethesda, MD, US.
- 2025. Demystifying clinical trials and promoting diverse participation. Invited. Indiana University Lung Cancer ECHO (Extension for Community Healthcare Outcomes) Series. Indianapolis, IN, US.
- 2025. Updates in immunotherapy for locally advanced unresectable NSCLC. Invited. 2025 Oklahoma Thoracic Oncology Conference. Oklahoma City, OK, US.
- 2025. Understanding Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. Invited. 2025 Cancer GRACE Targeted Therapies in Lung Cancer- Virtual, US.
- 2025. Big Changes in Small Cell Lung Cancer. Invited. University of Iowa Hematology/Oncology Grand Rounds. Iowa City, IA, US.
- 2025. Game-Changing SCLC Drug Hits Clinic: What’s the Playbook for Community Oncology. Invited. Oncology News Central, US.
- 2025. FDA Approval, Big News Complicate EGFR-Mutated NSCLC Decisions. Invited. Oncology News Central, US.
- 2025. Educating, Empowering, and Engaging: A Focus on HER2 positive NSCLC. Invited. 2025 Medscape Live Symposium. Hunington Beach, CA, US.
- 2025. ADCs and Emerging Treatments in NSCLC. Panelist. Targeted Therapies in Lung Cancer Conference. Hunington Beach, CA, US.
- 2025. Targeted Oncology Community Lung Cancer Case. Invited. Targeted Oncology Community Lung Cancer. Dallas, TX, US.
- 2025. Simplifying Academic Science for Digital Audiences. Invited. 2025 Summit in Respiratory Medicine. Las Vegas, NV, US.
- 2024. 2024 Masters in Thoracic Oncology Summit. Invited. Obrixtamig US Medical National Advisory Board at MaTOS. Lake Tahoe, California, US.
- 2024. End Lung Cancer Now. Invited. McHenry-Sherman Scholarly Conference. Indianapolis, Indiana, US.
- 2024. Understanding and Managing Compassion Fatigue in Medical Practice, IASLC World Conference on Lung Cancer Selected Workshop. Invited. World Conference Lung Cancer. San Diego, California, US.
- 2024. Exploring HER2 in NSCLC: Defining Gaps and Current Practices. Invited. Medscape Oncology, US.
- 2024. Binaytara Foundation Best of ASCO 2024: Updates in Small Cell Lung Cancer. Albuquerque, New Mexico, US.
- 2024. Case Based Roundtable: Immunotherapy in NSCLC-Virtual. Invited. Targeted Oncology, US.
- 2024. Leveraging Social Media for Career Growth. Expert Faculty Panelist ASCO 2024 Annual Meeting. Chicago, Illinois, US.
- 2024. “The Priciest Thing to Do Is to Blindly Treat” NSCLC, US.
- 2024. If You Have “One Shot on Goal” in EGFR-Mutated NSCLC, Which Approach Is Best?, US.
- 2024. Navigating Advocacy, Mentorship, and More in NSCLC Management. OncLive with MedNewsWeek, US.
- 2024. ASCO Virtual Mentoring Program, US.
- 2024. “Basics” of Lung Cancer for the Community. Invited. Houston, Texas, US.
- 2024. Early-Career Round Table Session. Invited. Santa Monica, California, US.
- 2024. Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice. Coral Gables, Florida, US.
- 2023. Biomarker Testing in Non-Small Cell Lung Cancer: Practical Application. OncLive. Houston, Texas, US.
- 2023. Meharry Medical College Medical Grand Rounds: Making the Right Call- Biomarker Testing and Targeting in NSCLC. Nashville, Tennessee, US.
- 2023. WCLC23 Interview Research Updates, US.
- 2023. OncLive Biomarker Consortium for Lung Cancer. Nashville, Tennessee, US.
- 2023. Immunotherapy-Induced Encephalitis: A Case of a Rare but Serious Complication of Anti-PD-1 Treatment. MD Anderson Cancer Center IOTOX Research Retreat. Houston, Texas, US.
- 2023. Tailoring the treatment approach to resectable stage non-small cell lung cancer. Invited. Binaytara Foundation 2023 Updates on Hematology and Oncology. Houston, Texas, US.
- 2023. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adult patients with advanced non-small cell lung cancer. Conference. DAVA Oncoloy. Kona, HI, US.
- 2023. Chair: Locally Advanced NSCLC. Conference. Chair: Locally Advanced NSCLC. Santa Monica, CA, US.
- 2022. Testing for Targetable Mutations in NSCLC: Tissue vs. Liquid Biopsy. VuMedi, US.
International Presentations
- 2023. Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective. Conference. Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, SG.
Formal Peers
- 2025. Management of Metastatic Non Small Cell Lung Cancer with Driver Alterations: What to know in 2025. Houston, Texas, US.
- 2025. Management of Metastatic Non Small Cell Lung Cancer without Driver Alterations: What to know in 2025. Houston, Texas, US.
- 2024. Navigating Social Media: Overview for the Online Oncologist. Houston, Texas, US.
- 2024. Pulmonary Medicine Fellows Board Review: Lung Cancer. Houston, Texas, US.
- 2024. The Truth About Tobacco and Vaping. Houston, Texas, US.
- 2024. Tailoring the treatment approach to resectable non small cell lung cancer BTF's 2023 Updates on Hematology & Oncology. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer with Driver Alterations. Houston, Texas, US.
- 2024. Management of Metastatic Non Small Cell Lung Cancer without Driver Alterations. Houston, Texas, US.
- 2024. Lung Cancer Board Review Lecture. Houston, Texas, US.
- 2024. Treatment of Early-Stage and Locally Advanced NSCLC: A Chalk Talk for Oncology Fellows. Houston, Texas, US.
- 2024. MD Anderson Fellowship Journal Club Discussion: Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases Expert Medical Oncology Discussant. Houston, Texas, US.
- 2024. Lung Cancer Comprehensive Care Overview Nurses and Allied Healthcare Professionals Didactic Series. Houston, Texas, US.
- 2024. Treatment of Stage I to III NSCLC: Fellowship Didactic Talk. Houston, Texas, US.
- 2024. Immunotherapy in the management of patients with metastatic non-small cell lung cancer. Houston, Texas, US.
- 2023. Navigating Social Media: A Guide for the Online Oncologist. Invited. Houston, TX, US.
- 2023. Tailoring the treatment approach to resectable non small cell lung cancer. Invited. Houston, TX, US.
- 2023. Navigating Social Media as an Oncologist. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | MD Anderson Young-Onset Lung Cancer Center (YOLCC) Initiative, Rexanna's Foundation for Fighting Lung Cancer, Lance Bertrand Research Grant Funded Project |
| Funding Source: | Lance Bertrand Research Grant Funded Project |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | “Investigating Clinical Outcomes in Young Adults with Non-Small Cell Lung Cancer,” Rexanna's Foundation for Fighting Lung Cancer |
| Funding Source: | Victor Elias Research Grant Funded Project |
| Role: | PI |
| Date: | 2024 - 2031 |
| Title: | A Pilot study to assess the Concordance Between MyBreathPrint Device results and Tissue Biopsy in patients with suspected lung cancer: Single center, single arm, prospective, observational design |
| Funding Source: | N/A |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
- Owen DH, Ismaila N, Ahluwalia A, Feldman J, Gadgeel S, Mullane M, Naidoo J, Presley CJ, Reuss JE, Singhi EK, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3. J Clin Oncol 43(10):e2-e16, 2025. e-Pub 2025. PMID: 40014839.
- Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40126456.
- Henley, M, DeCotiis, G, FitzGibbon, H, Singhi, EK. Decoding clinical trial jargon. Future Oncology 21(1):11-14, 2025. e-Pub 2025. PMID: 39692566.
- Sridhar A, West HJ, Singhi EK. Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer 25(7):e286-e294, 2024. e-Pub 2024. PMID: 38772808.
- Mysore M, Singhi D, Singhi EK. Caring for Your Heart During Cancer Treatment. JAMA Oncol 10(10):1447, 2024. e-Pub 2024. PMID: 39207763.
- Abu Rous F, Desai A, Singhi EK. Clinical Trials for Patients With Cancer. JAMA Oncol 10(3):416, 2024. e-Pub 2024. PMID: 38270965.
- Sridhar A, West H, Singhi EK. rief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2024.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The Democratization of Hematology-Oncology Medical Education during the COVID-19 Pandemic. Cancer Invest 41(6):548-558, 2023. e-Pub 2023. PMID: 37357925.
- Singhi EK, Mott F, Worse M, Leung CH, Lee JJ, Carter B, Presley CJ, Heymach JV, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. Oncol Lett 25(6):262, 2023. e-Pub 2023. PMID: 37216156.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, Singhi EK, Velazquez AI. The democratization of hematology-oncology medical education during the COVID-19 pandemic. Cancer Investigation 0:1-9, 2023. e-Pub 2023.
- Singhi EK, Feldman J, West HJ. The Multidisciplinary Cancer Conference. JAMA Oncol 9(2):288, 2023. e-Pub 2022. PMID: 36547939.
- Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung Cancer Treatment Advances in 2022. Cancer Invest 41(1):1-20, 2023. e-Pub 2022. PMID: 36036470.
- Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):236-243, 2022. e-Pub 2022. PMID: 35216923.
- Hu Z, Singhi EK, Apostolidou E, Mai B, Juneja HS, Hu S. Mass-forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia. Int J Lab Hematol 43(3):e135-e137, 2021. e-Pub 2021. PMID: 33314782.
- Singhi EK, Mott F, Worst M, Borg M, Johnson D, Lewis J, etal. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer. Journal for Immunotherapy of Cancer, 2021. e-Pub 2021.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ 35(5):1034-1040, 2020. e-Pub 2020. PMID: 32888144.
- Feld E, Singhi EK, Phillips S, Huang LC, Shyr Y, Horn L. Palliative Care Referrals for Advanced Non-small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices. Clin Lung Cancer 20(3):e291-e298, 2019. e-Pub 2019. PMID: 30862422.
- Singhi EK, Li BC, Denny JC. Simmering Below the Surface: Sweet's Syndrome with Multiple Myeloma. Am J Med 131(9):1058-1060, 2018. e-Pub 2018. PMID: 29729238.
- Singhi EK, Moore DC, Muslimani A. Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. P T 43(7):410-429, 2018. e-Pub 2018. PMID: 30013298.
- Patel K, Patel M, Gor A, Naidu S, Nathwani N, Kothadia R, Parekh S, Singhi EK. Oncology practice transformation helps deliver patient-centered cancer care in a community oncology practice. The American Journal of Managed Care, 2018. e-Pub 2018.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, etal. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension, 2017. e-Pub 2017.
- Singhi EK, Pommerenke AW, Mushtaq S, Cummings KM, etal. Addressing tobacco use at NCI designated cancer centers: Online resources available for patients. Journal of Clinical Oncology, 2015. e-Pub 2015.
- Nikolova YS, Singhi EK, Drabant EM, Hariri AR. Reward-related ventral striatum reactivity mediates gender-specific effects of a galanin remote enhancer haplotype on problem drinking. Genes Brain Behav 12(5):516-24, 2013. e-Pub 2013. PMID: 23489876.
- Singhi EK. The Power in Patient Education: A Collaborative Approach to Cancer Care.
- Singhi EK, Dupuis MM, Ross JA, Rieber AG, Bhadkamkar NA. Medical Hematology/Oncology Fellows' Perceptions of Online Medical Education During the COVID-19 Pandemic. J Cancer Educ. PMID: 32888144.
Invited Articles
- Singhi EK, Halmos B. Deciding Between Frontline Regimens in Advanced-Stage, EGFR-Mutant NSCLC: Is There a Place for More Intense Combinations Vs Osimertinib in the Treatment Landscape?, 2024.
- Singhi EK, West HJ. Rethinking the treatment approach to resectable non-small cell lung cancer: do new approvals always translate to clinical value. ASCO Daily News, 2023. e-Pub 2023.
- Mushtaq S, Singhi EK, Stuart R. Triple-triple hit lymphoma. Case Reports in Internal Medicine, 2015. e-Pub 2015.
Review Articles
- Singhi EK, Gay CM. Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer. Transl Lung Cancer Res 9(5):2051-2058, 2020. e-Pub 2020. PMID: 33209625.
- Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Am Soc Clin Oncol Educ Book 39:e187-e197, 2019. e-Pub 2019. PMID: 31099642.
- Singhi EK, Horn L. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol 14(18):1781-1787, 2018. e-Pub 2018. PMID: 29506392.
- Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension 71(2):e1-e8, 2018. e-Pub 2018. PMID: 29279311.
Other Articles
- Singhi EK, West HJ When Practice Evolves Faster Than the Data in Early-Stage Non–Small Cell Lung Cancer. ASCO Daily News, 2022.
Editorials
- Singhi EK. Disseminated Intravascular Coagulation (DIC). Vanderbilt University Medical Center Commodore Compendium, 2019.
Abstracts
- Singhi EK, Desai A, Abu Rous F, Feldman J. Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective. Journal of Thoracic Oncology 18(11):S65-S66, 2023. e-Pub 2023.
- Williams LA, Whisenant MS, Malveaux D, Singhi EK, Altan M. Patient Experience of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer, 2023. e-Pub 2023.
- Singhi EK, Mott F, Worst M, Hong Leung C, Lee J, Carter B, Presley C, Lewis J, Rinsurongkawong W, RinsurongKawong V, Zhang J, Gibbons D, Vaporciyan A, Heymach J, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer 9(Suppl 2), 2021. e-Pub 2021.
Books (edited and written)
- Abu Rous, F, Desai, A, Singhi, EK. Clinical Trials for Patients With Cancer, 2024.
Web Publications
- Singhi EK. Compassion Fatigue: How Oncologists Can Recognize the Signs, 2025.
- Singhi EK. Understanding the benefit of subcutaneous versus IV opdivo in patients with solid tumors, 2025.
- Singhi EK. mRNA Lung Cancer Vaccine Could Be Revolutionary Treatment, 2024.
- Singhi EK. OncLive Biomarker Consortium – NSCLC, Editor-in-chief, 2024.
- Singhi EK. Small Cell Lung Cancer (SCLC) Algorithm, 2024.
- Singhi EK. Top Lung Cancer Digital Opinion Leaders of #ASCO24, KOL Pulse AI, 2024.
- Singhi EK. OncoAlert International Team “Associate Faculty” for Thoracic Oncology, 2024.
- Singhi EK. Day in the Life of a Medical Oncologist, 2024.
- Singhi EK. Media Interview Training Course, 2024.
- Singhi EK. Top 4 Key Opinion Leaders in Lung Cancer by Engagement, 2024.
- Singhi EK. Top 100 Xfluencer in Lung Cancer, 2023.
- Singhi EK. MedNewsWeek Medical Spotlight: Navigating Non-small cell lung cancer—a journey of advocacy, discovery, mentorship, and patient-centered care, 2023.
- Singhi EK. Debunking myths about Lung Cancer, 2023.
- Singhi EK. Lead Moderator, @LungCancerRx Twitter Live Journal Club: Updated overall survival results of the phase 3 ADAURA study, 2023.
- Singhi EK. It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC, 2023.
- Singhi EK. 5 questions to ask a medical oncologist during your first visit, 2023.
- Singhi EK. Co-founder of @LungCancerRx Twitter profile, International social media profile dedicated to education for colleagues and patients on advancements in lung cancer, 2023.
- Singhi EK. Metastatic Non-Small Cell Lung Cancer (NSCLC) Algorithm without Targetable Mutations, 2022.
- Singhi EK. Busting 5 Myths about Lung Cancer, 2022.
- Singhi EK. Invited faculty, ASCO 2022 Updates Twitter Space, 2022.
- Singhi EK. NSCLC Section Editor, 2022.
- Singhi EK. theMedNet.org, 2022.
Patient Reviews
CV information above last modified October 29, 2025